Eli Lilly Weight-Loss Drug Zepbound Shows Superior Results to Wegovy in Phase 3 Study

MT Newswires Live
05-12

Eli Lilly (LLY) said Sunday that its weight-loss drug showed results superior to Novo Nordisk's (NVO) Wegovy in a phase 3 study evaluating the safety and efficacy of the two drugs over 72 weeks in obese or overweight patients with at least one weight-related medical problem and without diabetes.

The company asid Zepbound met its primary endpoint of weight loss, reducing weight by 20.2% or 50.3 pounds compared to 13.7% or 33.1 pounds for Wegovy.

The drug also met all five of its secondary endpoints in the study, the company said.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10